Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NanoRepro AGFRA:NN6 53 3-Year ROIIC % is 180.17 as of Dec. 2024, which is 760% above its 10-year median of 20.94. GuruFocus rates FRA:NN6 with a GF Score™ of 53/100 and a GF Value™ of €0.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 86.7% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
NanoRepro AG's 3-Year ROIIC % for the quarter that ended in Dec. 2024 was 180.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for NanoRepro AG's 3-Year ROIIC % or its related term are showing as below:
FRA:NN6's 3-Year ROIIC % is ranked better than 86.7% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs FRA:NN6: 180.17
NanoRepro AG (FRA:NN6) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
NanoRepro AG 3-Year ROIIC % Related Terms
NanoRepro AG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NN6 vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's 3-Year ROIIC % falls into.
NanoRepro AG's 3-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.57784 (Dec. 2024) - 30.3117225 (Dec. 2021) )
/
( 29.634 (Dec. 2024) - 47.889 (Dec. 2021) )
=
-32.8895625
/
-18.255
=
180.17%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
NanoRepro AG (FRA:NN6) has a 3-Year ROIIC % of 180.17 as of Dec. 2024. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NanoRepro AG and its competitors. This is 760% above median its historical median of 20.94. According to the industry distribution chart, NanoRepro AG ranks #27 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 13.3%.
Is NanoRepro AG's 3-Year ROIIC % too high?
NanoRepro AG's current 3-Year ROIIC % of 180.17 is 760% above median its 10-year median of 20.94. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. NanoRepro AG's value of 180.17 is 81795.5% above this industry median. Based on the distribution chart, NanoRepro AG ranks #27 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NanoRepro AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #27 out of 203 companies for 3-Year ROIIC %. This places NanoRepro AG in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. NanoRepro AG's value of 180.17 is 81795.5% above this benchmark. While the company's 10-year median is 20.94 vs. the industry median of 0.22, NanoRepro AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current 3-Year ROIIC % of 180.17 is 81795.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current 3-Year ROIIC % is 180.17, which is 760% above median its own 10-year median of 20.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (FRA:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.99, compared to a current price of €2.10 — trading 112.1% above its estimated fair value. The current 3-Year ROIIC % is 180.17, which is 760% above median its 10-year median of 20.94 and 81795.5% above the Medical Diagnostics & Research industry median of 0.22. NanoRepro AG's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For NanoRepro AG (FRA:NN6), the current 3-Year ROIIC % is 180.17 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (FRA:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.10 is trading 112.1% above its estimated GF Value™ of €0.99.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for FRA:NN6:
3-Year ROIIC %: 180.17 (760% above median its 10-year median of 20.94)
GF Value™: €0.99 vs. price of €2.10 (112.1% above fair value)
Industry Position: 81795.5% above the Medical Diagnostics & Research median (#27 of 203)
No single metric tells the full story. See the FRA:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
53GF Score
Get the complete analysis for FRA:NN6
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NN6 has been successfully added to your 
